Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$7.58 - $12.25 $2.65 Million - $4.29 Million
-350,000 Reduced 65.99%
180,400 $2.21 Million
Q3 2023

Nov 13, 2023

BUY
$8.95 - $11.35 $4.75 Million - $6.02 Million
530,400 New
530,400 $5.11 Million

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $210M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.